ProdromeNeuro Alzheimer’s Clinical Trial Published

The results from our clinical trial with Dr. Sheldon Jordan are now published in a peer reviewed journal here.

ProdromeNeuroTM plasmalogen supplement successfully improved cognition and mobility in a recent Alzheimer’s disease clinical trial, proving Dr. Dayan Goodenowe’s 15-year theory outlined in his new book Breaking Alzheimer’swhere he explains his scientific journey to expose the cause and deliver the cure.

Prodrome Sciences launched the world’s first high-dose plasmalogen supplement, ProdromeNeuro, in 2020. A clinical trial was initiated shortly thereafter. The clinical trial results were released at the Alzheimer’s Association International Conference on July 26, 2021. ProdromeNeuro supplement successfully improved cognition and mobility in persons diagnosed with mild to moderate cognitive impairment. Conducted by Dr. Sheldon Jordan (MD), a board-certified neurologist at the Neurological Associates Clinic in Santa Monica, California. The success of the trial is the result of Dr. Dayan Goodenowe (PhD)’s relentless 15-year scientific journey, as outlined in his book Breaking Alzheimer’s just released June 21, 2021.

“My work on plasmalogen molecules started over 15 years ago when I discovered that plasmalogen deficiency was the major causative factor in Alzheimer’s disease. I am pleased that my scientifically-designed supplements, which have undergone extensive preclinical testing and validation, have been shown to perform in persons suffering from cognitive impairment exactly as designed. This new clinical evidence is just the beginning.” – Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences based in Temecula, CA.

Improved cognition is absolutely the dream of any Alzheimer’s treatment, although the status quo has accepted that a treatment to just halt the disease from getting any worse is a realistic goal to strive for. Not only did the ProdromeNeuro Plasmalogen supplement stabilize cognition in 82% of the clinical trial participants, but cognition incredibly improved in 41% of participants! Mobility is also greatly affected in Alzheimer’s disease, and with ProdromeNeuro mobility also remained stable in 82% but was improved in even more participants – 55%. In total, 73% of participants experienced either increased cognition or increased mobility or both after only four months of supplementation.

The clinical trial results are truly ground breaking and motivating. As Dr. Goodenowe explains, “science is a slow process, but an important process, and it is never over. It took 15 years of hard work to get to this important milestone. Results like this fuel me and my team to keep up the hard work ahead. The next step is to prove on a larger, rigorous scale, that my programs, which include plasmalogens and my patented blood testing technology, can be used to prevent and treat Alzheimer’s and other age-related diseases on a population level so that entire countries can have effective programs to reduce diseases and their emotional and economic burden. This next chapter has already begun.”

Dr. Goodenowe’s 15-year journey that made this clinical trial possible is outlined in his book, Breaking Alzheimer’s, released June 21, 2021. It all started with his powerful invention in 1999 that allowed him to look at blood samples in a way never before imagined. This invention remains the most advanced of its kind even today. A new world opened up to Dr. Goodenowe where he could see the active processes inside the body through thousands of molecules; he became an expert in understanding the story those molecules were telling. One of those stories was plasmalogen deficiency in Alzheimer’s disease, which he discovered in 2004 after analyzing thousands of blood samples from Alzheimer’s patients from around the world.

After rigorous scientific study, Dr. Goodenowe, who not only can invent blood testing technology and is an expert in neuroscience but is also an expert in synthetic organic chemistry, designed and developed the world’s first high-dose plasmalogen supplement which launched commercially in 2020 and now has hundreds of doctors using it with their patients all over the world.

Advance praise for Dr. Goodenowe’s book, Breaking Alzheimer’s, and for his work, includes:

“A paradigm-altering view of Alzheimer’s.”
Dale Bredesen, MD 
Author of The New York Times Bestseller The End of Alzheimer’s

“A brilliant and ground-breaking text on the science and clinical application of plasmalogens for the therapeutic amelioration of Alzheimer’s Dementia. I have had the good fortune of observing firsthand the significant, clinical benefits in my patients with neurodegenerative disorders for whom I’ve prescribed plasmalogen therapy.”
Mitchel Fleisher M.D., D.Ht., D.A.B.F.M., Dc.A.B.C.T.
Medical Director, Center for Integrative & Regenerative Medicine

“A bold and promising approach. Dr. Goodenowe has performed groundbreaking and compelling research which is detailed in the book so that afflicted patients and health professionals will become aware of a discovery which may very well change our approach to Alzheimer’s. We have been deploying plasmalogen precursors at the Regenesis Project and have found that within the timeframe of a few weeks, people become more alert and cognizant.”
Sheldon Jordan, MD, FAAN, DABPN, DABCN
Medical Director, the Regenesis Project

“Dayan Goodenowe has drilled down to the very core of what makes us tick. His patient 25 year journey of research and invention has unpacked unique and marvelous understanding into how our metabolic engine works. We have a whole new field of medicine opening up called “metabolic medicine” and it runs right through Dr. Goodenowe’s inventions. Like tuning your carburetor and timing your engine, we can now heal your mitochondria and make your peroxisomes whistle with the careful measurement and replacement of plasmalogens. The implications of his inventions can’t be overstated. This is the end of Alzheimer’s, Parkinson’s, cancer….and who knows what lies ahead in the paradigm shift to true wellness with the absence of disease.”
John E. Whitcomb, MD
Brookfield Longevity Medical Clinic

The testimonials from doctors and patients using the Prodrome products are powerful. Clinical trial evidence is critical to advance plasmalogen supplementation into the mainstream so that everyone can benefit.

The recent ProdromeNeuro Plasmalogen supplement clinical trial involved 22 participants diagnosed with mild to moderate cognitive impairment. The trial lasted 5 months, with an escalating dose of ProdromeNeuro at 900mg/day for month one, 1800mg/day for months two and three, and 3600mg/day for month four, and the final month was 0mg/day for a washout. Blood sample collection and clinical evaluations were performed at the start of the trial and at the end of each month. The dose was important: 1800mg/day appeared sufficient for most participants while one participant began to see clinical benefit at 3600mg/day. ProdromeNeuro was well tolerated at all doses and no adverse events were reported. The next step is to design a larger clinical trial for a longer duration to further investigate the optimal ProdromeNeuro Plasmalogen supplement dose.

Plasmalogen molecules are a major building block of the body and make up to 20% of the brain. They are also found in high concentrations in the heart, lungs, retina, and kidney and are found in every cell of the body. Levels decrease with age as the body can no longer keep up with the demand as plasmalogens are used up by the body as powerful antioxidants and anti-inflammatory molecules. High doses are needed to effectively replenish and maintain levels in the body.

The recent success of the ProdromeNeuro Plasmalogen supplement clinical trial is an important milestone for Alzheimer’s disease and dementia. Plasmalogens are implicated in numerous diseases; clinical trials in Parkinson’s disease, multiple sclerosis, and autism are needed. Dr. Goodenowe continues the plasmalogen story by building evidence and designing effective, viable programs that can be implemented on a population-wide level so that his life-saving technology can benefit the world.

About Prodrome Sciences
Prodrome Sciences is a specialty laboratory and supplement manufacturing company and offers proprietary blood tests to measure biomarkers for health and disease. Products are the result of extensive scientific evidence from large clinical studies of thousands of blood samples from around the world. Prodrome Sciences researches and develops solutions to prevent disease, improve health and vitality, and achieve longevity.

Media Contact:
Erika Shklanka
Chief Operating Officer
Prodrome Sciences
Tel: 1-951-550-0505

Related Links

Dr. Dayan Goodenowe presents the results and data in detail in his free educational seminars. To view the presentations, register for the seminars here and navigate to seminars C105 and C106. View the article for C105 here and the article for C106 here.

Share on facebook
Share on twitter
Share on linkedin
Your privacy is important to us.

To better protect your privacy, we provide this notice explaining our online information practices and the choices you can make about the way your information is collected and used. To make this notice easy to find, we make it available on our homepage and at every point where personally identifiable information may be requested.

Collection of Personal Information

When visiting, the IP address used to access the site will be logged along with the dates and times of access. This information is purely used to analyze trends, administer the site, track users’ movement and gather broad demographic information for internal use. Most important, any recorded IP addresses are not linked to personally identifiable information.

Links to Third-Party Websites
We have included links on this site for your use and reference. We are not responsible for the privacy policies on these websites. You should be aware that the privacy policies of these sites may differ from our own.
Our Use of Google Analytics
The Dr. Dayan Goodenowe website uses the Google Analytics tool to measure traffic on the site and traffic to the site via our online advertising. This includes using certain Advertising Features, which enable Google Analytics to collect data about users via Google advertising cookies and identifiers, in addition to anonymous data collected through the standard Google Analytics implementation. These Advertising Features, which may or may not be currently using, include:
  • Remarketing with Google Analytics. This allows us to display our ads to you as you search online for similar businesses.
  • Google Display Network Impression Reporting, which shows which of our ads users click on.
  • Google Analytics Demographics and Interest Reporting, which provides information about the age and gender of site users, along with the interests they express in their online travel and purchasing activities.
  • Integrated services that require Google Analytics to collect data via advertising cookies and identifiers.
We do not merge personally identifiable information with non-personally identifiable information collected through any Google advertising product or feature unless we have obtained robust notice of, and the user’s prior affirmative (i.e., opt-in) consent to, that merger. These Advertising Features, which may or may not be currently using, include:
Opt Out

There are several ways to opt out of interest-based advertising and/or all tracking related to Google Analytics and its advertising features.

You can opt out of interest-based ads by Google through Ads Settings. When you opt out, you’ll still see ads but they may not be related to factors such as your interests, previous visits to other websites, or demographic details. Obtain instructions here.

The Network Advertising Initiative offers a free tool that allows users to opt out from receiving interest-based ads from some or all NAI participating member companies that use cookies on your computer browser to collect data for interest-based advertising. Find information about it here.

Website visitors can totally block Google Analytics with the Google Analytics opt-out browser add-on (click to download). This add-on instructs the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) running on websites to prohibit their information from being used by Google Analytics. Using the Google Analytics opt-out plug-in will not prevent site owners from using other tools to measure site analytics. Learn more about about the opt-out and how to properly install the browser add-on here.

Changes to this Privacy

Statement The contents of this statement may be altered at any time, at our discretion.

If you have any questions regarding the privacy policy of then you may contact us at

terms of use
Welcome to our website. If you continue to browse and use this website, you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern’s relationship with you in relation to this website. If you disagree with any part of these terms and conditions, please do not use our website.

The term ‘’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is:

40880 County Center Drive
Suite R
Temecula, CA 92591, USA

The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trademarks reproduced in this website, which are not the property of, or licensed to the operator, are acknowledged on the website.

Unauthorized use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time, this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).

Your use of this website and any dispute arising out of such use of the website is subject to the laws of Canada and USA.

We use cookies to make this site as useful as possible. They are small text files we put in your browser to track usage of our site but they don’t tell us who you are. If you want to delete any cookies that are already on your computer, please refer to the instructions for your file management software to locate the file or directory that stores cookies.

This site is not a part of the Facebook website or Facebook Inc. Additionally, this site is not endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.